Strategy for growth

Every day, we strive to build a broader and stronger Orexo. By doing so, we can improve many more lives, foster a more dynamic work environment, and generate value for our shareholders. Our efforts to strengthen and expand Orexo are built on three pillars and are driven by our ambition to contribute to a more sustainable world for all.

  • Optimize value contribution from Zubsolv®
  • Obtain FDA approval of Izipry™ and adapt go-to-market strategy to market potential.

  • OX390 development in partnership with BARDA to address growing issue with adulterated opioids
  • OX472 to enter the sizable and growing market for anti-obesity medication and other GLP-1 agonists
  • OX640 addressing the need for more convenient and stable formulation of epinephrine.

  • Become the partner of choice for nasal powder delivery 
  • Expand into large molecules through partnership and improve scientific proof of concept
  • Partner internal projects to secure financing while maintain substantial value share.

 

 

 

Sustainability strategy

Orexo’s business strategy and its day-to-day operationalization are shaped by the company’s Ethical Code. The strategy supports Agenda 2030 and the Sustainable Development Goals (SDGs). It is also aligned with global standards and initiatives, including the International Labor Organization Conventions, and the UN Guiding Principles on Business and Human Rights. The sustainability strategy consists of four focus areas:

Responsible business

Focus area 1

Access to healthcare

Focus area 2

Sustainable employees

Focus area 3

Environment & climate action

Focus area 4